A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer’s disease mouse model

[1]  J. Ji,et al.  SIRT1 facilitates amyloid beta peptide degradation by upregulating lysosome number in primary astrocytes , 2018, Neural regeneration research.

[2]  Xiangming Xu,et al.  Small Molecules as SIRT Modulators. , 2018, Mini reviews in medicinal chemistry.

[3]  N. Krogan,et al.  SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy , 2018, The Journal of Neuroscience.

[4]  Yixin Li,et al.  SIRT1/PGC-1α Signaling Promotes Mitochondrial Functional Recovery and Reduces Apoptosis after Intracerebral Hemorrhage in Rats , 2018, Front. Mol. Neurosci..

[5]  Fei Liu,et al.  SIRT1 Deacetylates SC35 and Suppresses Its Function in Tau Exon 10 Inclusion. , 2017, Journal of Alzheimer's disease : JAD.

[6]  G. Bu,et al.  ApoE4 Accelerates Early Seeding of Amyloid Pathology , 2017, Neuron.

[7]  R. Vassar.  Seeds of Destruction: New Mechanistic Insights into the Role of Apolipoprotein E4 in Alzheimer’s Disease , 2017, Neuron.

[8]  Qingqing Shi,et al.  Postnatal Administration of Dizocilpine Inhibits Neuronal Excitability in PFC and Induces Social Deficits Detected by MiceProfiler , 2016, Molecular Neurobiology.

[9]  G. Elder,et al.  ApoE4-associated phospholipid dysregulation contributes to development of Tau hyper-phosphorylation after traumatic brain injury , 2017, Scientific Reports.

[10]  N. Braidy,et al.  Resveratrol and Alzheimer’s Disease: Mechanistic Insights , 2017, Molecular Neurobiology.

[11]  A. Tripathy,et al.  A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy , 2017, Scientific Reports.

[12]  Dae-seung Yang,et al.  Treadmill exercise decreases amyloid-β burden possibly via activation of SIRT-1 signaling in a mouse model of Alzheimer's disease , 2017, Experimental Neurology.

[13]  Erin L. Abner,et al.  A Comprehensive Behavioral Test Battery to Assess Learning and Memory in 129S6/Tg2576 Mice , 2016, PloS one.

[14]  D. Bredesen,et al.  Direct Transcriptional Effects of Apolipoprotein E , 2016, The Journal of Neuroscience.

[15]  Y. Ouchi,et al.  Protective effects of NMDA receptor antagonist, memantine, against senescence of PC12 cells: A possible role of nNOS and combined effects with donepezil , 2015, Experimental Gerontology.

[16]  Amrendra P. Singh,et al.  REMOVED: Promising serum protein marker for early detection of Alzheimer's disease , 2015, International Journal of Developmental Neuroscience.

[17]  James B. Brewer,et al.  A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease , 2015, Neurology.

[18]  V. John.  Enhancement of sAPPα as a Therapeutic Strategy for Alzheimer’s and Other Neurodegenerative Diseases , 2015 .

[19]  N. Krogan,et al.  Critical Role of Acetylation in Tau-Mediated Neurodegeneration and Cognitive Deficits , 2015, Nature Medicine.

[20]  D. Bredesen,et al.  The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model , 2014, Brain Research.

[21]  L. Carboni,et al.  Human apolipoprotein E4 modulates the expression of Pin1, Sirtuin 1, and Presenilin 1 in brain regions of targeted replacement apoE mice , 2014, Neuroscience.

[22]  M. Greicius,et al.  Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction , 2013, Brain Imaging and Behavior.

[23]  D. Bredesen,et al.  Neuroprotective Sirtuin ratio reversed by ApoE4 , 2013, Proceedings of the National Academy of Sciences.

[24]  H. Rhinn,et al.  Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease , 2013, Nature.

[25]  A. Dey,et al.  Sirtuin1: A Promising Serum Protein Marker for Early Detection of Alzheimer’s Disease , 2013, PloS one.

[26]  Yadong Huang,et al.  Apolipoprotein E4 Causes Age- and Sex-Dependent Impairments of Hilar GABAergic Interneurons and Learning and Memory Deficits in Mice , 2012, PloS one.

[27]  R. Mahley,et al.  Small-molecule structure correctors target abnormal protein structure and function: structure corrector rescue of apolipoprotein E4-associated neuropathology. , 2012, Journal of medicinal chemistry.

[28]  E. Weeber,et al.  APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease* , 2012, The Journal of Biological Chemistry.

[29]  J. M. Villalba,et al.  Sirtuin activators and inhibitors , 2012, BioFactors.

[30]  A. Neves,et al.  Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. , 2012, Current medicinal chemistry.

[31]  M. Chesselet,et al.  Cognitive deficits in a mouse model of pre‐manifest Parkinson’s disease , 2012, The European journal of neuroscience.

[32]  M. Antunes,et al.  The novel object recognition memory: neurobiology, test procedure, and its modifications , 2011, Cognitive Processing.

[33]  J. Terao,et al.  Accumulation of orally administered quercetin in brain tissue and its antioxidative effects in rats. , 2011, Free radical biology & medicine.

[34]  Hyoung-Gon Lee,et al.  The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations , 2011, The Lancet Neurology.

[35]  G. Pasinetti,et al.  The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology. , 2010, Biochimica et biophysica acta.

[36]  D. Bredesen.  Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence , 2009, Molecular Neurodegeneration.

[37]  L. Guarente.  Hypoxic Hookup , 2009, Science.

[38]  F. Fahrenholz,et al.  Up‐regulation of the α‐secretase ADAM10 by retinoic acid receptors and acitretin , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  Francisco J Alcaín,et al.  Sirtuin activators , 2009, Expert opinion on therapeutic patents.

[40]  D. Bennett,et al.  Sirtuin 1 Reduction Parallels the Accumulation of Tau in Alzheimer Disease , 2009, Journal of neuropathology and experimental neurology.

[41]  P. Elliott,et al.  Sirtuins: novel targets for metabolic disease. , 2008, Current opinion in investigational drugs.

[42]  L. Guarente.  Mitochondria—A Nexus for Aging, Calorie Restriction, and Sirtuins? , 2008, Cell.

[43]  R. Mahley,et al.  Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease. , 2007, Current Alzheimer research.

[44]  M. Amri,et al.  Effect of Resveratrol on Antioxidant Enzyme Activities in the Brain of Healthy Rat , 2007, Neurochemical Research.

[45]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[46]  Walter A. Korfmacher,et al.  Rapid in vivo oral screening in rats: Reliability, acceptance criteria, and filtering efficiency , 2006, The AAPS Journal.

[47]  L. Mucke,et al.  SIRT1 Protects against Microglia-dependent Amyloid-β Toxicity through Inhibiting NF-κB Signaling* , 2005, Journal of Biological Chemistry.

[48]  D. Sinclair.  Toward a unified theory of caloric restriction and longevity regulation , 2005, Mechanisms of Ageing and Development.

[49]  Alcino J. Silva,et al.  Notch to remember , 2005, Trends in Neurosciences.

[50]  T. Morgan,et al.  Caloric restriction attenuates Aβ-deposition in Alzheimer transgenic models , 2005, Neurobiology of Aging.

[51]  D. Schmechel,et al.  Marked regional differences of brain human apolipoprotein e expression in targeted replacement mice , 2004, Neuroscience.

[52]  C. Lanni,et al.  Acetylcholinesterase inhibitors: novel activities of old molecules. , 2004, Pharmacological research.

[53]  Dominic M. Walsh,et al.  Deciphering the Molecular Basis of Memory Failure in Alzheimer's Disease , 2004, Neuron.

[54]  M. Mayo,et al.  Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase , 2004, The EMBO journal.

[55]  Steven P. Gygi,et al.  Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase , 2004, Science.

[56]  D. Begley,et al.  Flavonoid permeability across an in situ model of the blood-brain barrier. , 2004, Free radical biology & medicine.

[57]  S. Minucci,et al.  Human SIR2 deacetylates p53 and antagonizes PML/p53‐induced cellular senescence , 2002, The EMBO journal.

[58]  Walter A. Korfmacher,et al.  Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery. , 2001, Rapid communications in mass spectrometry : RCM.

[59]  Masahiko Watanabe,et al.  Apo E structure determines VLDL clearance and atherosclerosis risk in mice. , 1999, The Journal of clinical investigation.

[60]  R. Tanzi,et al.  Potential therapeutic targets for Alzheimer’s disease , 1998 .

[61]  D. Dickson.  Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques? , 1997, The American journal of pathology.

[62]  C. Pidgeon,et al.  Immobilized-artificial-membrane chromatography: measurements of membrane partition coefficient and predicting drug membrane permeability. , 1996, Journal of chromatography. A.

[63]  J. Haines,et al.  Apolipoprotein E genotype in patients with alzheimer's disease: Implications for the risk of dementia among relatives , 1995, Annals of neurology.

[64]  M. Courtney,et al.  Alaproclate acts as a potent, reversible and noncompetitive antagonist of the NMDA receptor coupled ion flow. , 1994, The Journal of pharmacology and experimental therapeutics.

[65]  M. Rogawski,et al.  Alaproclate effects on voltage-dependent K+ channels and NMDA receptors: Studies in cultured rat hippocampal neurons and fibroblast cells transformed with Kvl.2 K+ channel cDNA , 1994, Neuropharmacology.

[66]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[67]  L. Bertilsson,et al.  Alaproclate a novel antidepressant? , 1985, Acta psychiatrica Scandinavica.

[68]  P. Jansson,et al.  A double‐blind comparison of alaproclate and placebo in the treatment of patients with senile dementia , 1985, Acta psychiatrica Scandinavica.

[69]  S O Ogren,et al.  Inhibitors of neuronal monoamine uptake. 2. Selective inhibition of 5-hydroxytryptamine uptake by alpha-amino acid esters of phenethyl alcohols. , 1978, Journal of medicinal chemistry.

[70]  C. W. Greene,et al.  THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY. , 1917, Science.

[71]  M. Ohno,et al.  Beneficial effects of the β-secretase inhibitor GRL-8234 in 5XFAD Alzheimer's transgenic mice lessen during disease progression. , 2015, Current Alzheimer research.

[72]  D. Bredesen,et al.  sAβPPα is a Potent Endogenous Inhibitor of BACE1. , 2015, Journal of Alzheimer's disease : JAD.

[73]  P. Elliott,et al.  Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. , 2013, British journal of clinical pharmacology.

[74]  K. Jin,et al.  Notch signaling and neurogenesis in normal and stroke brain. , 2009, International journal of physiology, pathophysiology and pharmacology.

[75]  F. Fahrenholz,et al.  Up-regulation of the (cid:1) -secretase ADAM10 by retinoic acid receptors and acitretin , 2009 .

[76]  H. Hall,et al.  Alaproclate, a new selective 5-HT uptake inhibitor with therapeutic potential in depression and senile dementia , 2005, Journal of Neural Transmission.

[77]  L. Mucke,et al.  SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. , 2005, The Journal of biological chemistry.

[78]  E. Marshall,et al.  Alaproclate — an open clinical study in depressive illness , 2004, Psychopharmacology.

[79]  G. Bråne,et al.  Alaproclate: A pharmacokinetic and biochemical study in patients with dementia of Alzheimer type , 2004, Psychopharmacology.

[80]  S. Ögren,et al.  Role of serotonin in memory: facilitation by alaproclate and zimeldine , 2004, Psychopharmacology.

[81]  Mechanistic insights , 2022 .